Discussion
Lexeo Therapeutics has acquired the private, clinical-stage company Mantle Therapeutics, gaining the rights to several experimental therapies Mantle had been developing for Friedreich’s ataxia (FA) — including one already in early clinical testing. In announcing the deal, which could be worth more than $21 million, Lexeo also heralded…
